All News
Bridging the gap in the delayed diagnosis of axSpA
Delay in the diagnosis of axial spondyloarthritis (axSpA) has been a huge challenge and is associated with poor outcomes.
Read Article
Marc Hochberg lecture at #ACR21 - Bisphosphonates limited and inconclusive data in radiographic progression of OA, some ⬇️ in bone marrow lesions!
@RheumNow https://t.co/ciMUINBLwm
Bella Mehta bella_mehta ( View Tweet)
Abst 0981
Interesting study by Singer & colleagues examining economical and clinical burden of herpes zoster in patients with RA
- RA + HZ --> higher odds health resource utilization
- RA + HZ --> higher costs $$$
#ACR21 @RheumNow https://t.co/6Oc7ymbKHQ
Akhil Sood MD AkhilSoodMD ( View Tweet)
TOFA Post hoc analysis on 2000pts:
⬆️ Paraoxonase PON1 activity associated w/
⬇ risk of malignancies (not NMSC) in RA pts treated w/ TOFA, Adj on RA duration, age, and smoking.
A promising biomarker! #Abst980 @RheumNow #ACR21 https://t.co/fOILnAyDN9
Aurelie Najm AurelieRheumo ( View Tweet)
Real-world data shows no difference between genders in effectiveness of secukinumab in #AnkylosingSpondylitis, for disease activity, global functioning and severity of depression.
#Abs0909 #ACR21 @RheumNow
https://t.co/2n6Y5ZB1Ot https://t.co/zIMEzHBUrh
Mrinalini Dey DrMiniDey ( View Tweet)
Dr. Marc Hochberg delivering the Oscar Gluck Memorial lecture - His talk titled "The Role of Bone in OA". He begins with this statement.... "DJD... Should never be used" - the rest of the lecture explains why. #ACR21 https://t.co/lYGsFu4Wpr https://t.co/IWP5J73mFO
Links:
Dr. John Cush RheumNow ( View Tweet)
#Abs0588 Effectiveness of TNFi vs non-TNFis in obese patients with #rheumatic disease @MilenaGianfran:
👉🏼>16000pts @ACRheum RISE
👉🏼Abatacept➡️larger decreases in CDAI in obese pts
👉🏼Tocilizumab➡️larger decreases in CDAI in non-obese pts
@RheumNow #ACR21
https://t.co/bL5xnG1iNh
Mrinalini Dey DrMiniDey ( View Tweet)
B cell repertoire: the new 🔮?
An algorithm associating baseline CDAI to BCR sequencing outcomes w/
✨Isotypes frequency
✨Somatic Hypermutations
predicts MTX 12mo response w/ 78% sens & spe
#Abstr982 #ACR21 @RheumNow
https://t.co/SZaip6xUaO https://t.co/fbWq34gtzc
Aurelie Najm AurelieRheumo ( View Tweet)
Dusting off the old emergency supply right now (and there’s a lot of dust).
See? It said it on the side of the bottle all this time… they knew.
#ACR21 ABST0957 @RheumNow https://t.co/ygw6BkkjEp https://t.co/DqbIP8uL68
David Liew drdavidliew ( View Tweet)
Does #comorbidity burden affect treatment of #InflammatoryArthritis?
Abs#0577 #ACR21
👉🏼~6500pts; 11 types of IA
👉🏼Higher comorbidity burden➡️more likely to receive steroids than TNFis
👉🏼Are patients w/ IA & multiple comorbidities receiving suboptimal therapy?
@RheumNow #ACRBest https://t.co/iIERb0wL4Y
Mrinalini Dey DrMiniDey ( View Tweet)
Stop by the RheumNow booth! #ACR21 #RheumPix https://t.co/e9dEwkfXU9
Dr. John Cush RheumNow ( View Tweet)
#ACR21 #Abstr0866 Data from #COVID19 GRA Registry showed predictors of poor COVID outcome in 1922 #lupus pts:
Older age
Male
Areas outside Europe, 🇺🇸🇨🇦
Infection <June 2020
Any Corticosteroid dose
Not on therapy
On Rituximab
Comorbidities
⬆️disease activity
@RheumNow #ACRBest https://t.co/u0GF3aDsFA
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Predictors of clinical remission in AS patients Rx with TNFi
⭐️Age and 3-mo BASDAI improvement➡️ predictor of clinical remission criteria
⭐️Normalized ESR and CRP at month 3 were predictors of achievement of BASDAI-CRP
Abst#0931 #ACR21 @RheumNow https://t.co/Ot1ypgNg3A
swethaann23 swethaann23 ( View Tweet)
Had the pleasure of interviewing @MyasoedovaElena from Mayo Clinic on Cognitive Function and RA
#ACR21 @RheumNow
https://t.co/SuXeMhUvk0
Akhil Sood MD AkhilSoodMD ( View Tweet)
In general low health literacy has ⬆️association with non adherence in chronic disease Rx including gout prevention but many other reasons for non adherence cross the health literacy divide. Ex use of alternative Rx, denial, side effects, advice from non HCPs #ACR21 @RheumNow https://t.co/mIIndW1FnV
Janet Pope Janetbirdope ( View Tweet)
Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission:
⭐️🔼Baseline physician global VAS 🔼flare in 16 weeks after tapering to 2/3 of standard dose.
⭐️🔼Age 🔼flare within 16 weeks after tapering to 1/2 dose
Abst #0929 #ACR21 @RheumNow https://t.co/EFiwKA8z99
swethaann23 swethaann23 ( View Tweet)
My video take on this from yesterday for @RheumNow:
'11 Ways to Stay Away From RA' #ACR21
https://t.co/ELZaL1A20i https://t.co/bynPNibk3q
Links:
David Liew drdavidliew ( View Tweet)
Clinical pearls on Erdheim-Chester disease:
➕"Hairy Kidneys" on CT
➕"Coated" aorta or periaortitis
➕PET scan can confirm diagnosis - affects distal long bones
➕Refer to Oncology for treatment - it's a histiocytic neoplasm!🤓
@RheumNow #ACR21 #MedTwitter https://t.co/MsIqk1rWvE
sheila RHEUMarampa ( View Tweet)
RheumNow’s expanded coverage of the #ACR21 annual meeting is sponsored in part by @Novartis. All content chosen by #RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
My video take from yesterday for @RheumNow:
'Tired of Doing Nothing About Fatigue' #ACR21
https://t.co/EXjOibL5s9 https://t.co/cR6r8GdDor
Links:
David Liew drdavidliew ( View Tweet)